Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting

作者：Simone Ribero, Alice Ramondetta, Gabriella Fabbrocini, Vincenzo Bettoli, Concetta Potenza, Andrea Chiricozzi, Matteo Licciardello, Angelo Valerio Marzano, Luca Bianchi, Giulia Rozzo, Luca Fania, Claudio Marasca, Giulia Odorici, Alessandra Mambrin, Chiara Moltrasio, Raffaele Dante Caposiena, Nevena Skroza, Pietro Quaglino, Niccolò Siliquini, Paolo Dapavo · 发表于：Journal of the European Academy of Dermatology and Venereology · 年份：2021 · DOI：10.1111/jdv.17178 · 被引用次数：51 · 研究领域：Hidradenitis Suppurativa and Treatments、Colorectal and Anal Carcinomas、Chemotherapy-related skin toxicity

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Albeit, its pathogenesis, is multifactorial; HS is regarded as mainly auto-inflammatory in its origin.1 In partic- ular, the high expression levels of interleukin (IL)-17A in the bloodstream2 and in lesional skin3,4 of patients with HS, allow us to consider secukinumab as a potential drug capable of arrest- ing the inflammatory cascade that characterizes this complicated pathology. We carried out a multicentric retrospective study collecting 31 patients.